We agree with Lega and colleagues[1][1] that menopausal hormone therapy (MHT) has been shown in randomized controlled trials (RCTs) to be effective and safe for treating problematic vasomotor symptoms related to menopause. We also agree that treating menopausal vasomotor symptoms is important to
PMID 37524397 37524397 DOI 10.1503/cmaj.148952-l 10.1503/cmaj.148952-l
Cite this article
Prior, J. C., Hitchcock, C. L., Shirin, S., Hale, G., & Goshtasebi, A. (2023). Don't ignore perimenopause. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne*, *195*(29), E987. https://doi.org/10.1503/cmaj.148952-l
Prior JC, Hitchcock CL, Shirin S, Hale G, Goshtasebi A. Don't ignore perimenopause. CMAJ. 2023;195(29):E987. doi:10.1503/cmaj.148952-l
Prior, J. C., et al. "Don't ignore perimenopause." *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne*, vol. 195, no. 29, 2023, pp. E987.
Prior JC et al., 2023
Open Access
Scientific Reports
This study tested progesterone for perimenopausal hot flush ± night sweat (vasomotor symptom, VMS) treatment. It was a double-blind, randomized trial of 300 mg oral micronized progesterone@bedtime ver...
Early menopause (<45 years) has significant impacts on bone, cardiovascular, and cognitive health. Several studies have suggested earlier menopause for women living with HIV; however, the current lite...
Vigil P et al., 2022
Open Access
Frontiers in Endocrinology
Obesity in women of reproductive age has a number of adverse metabolic effects, including Type II Diabetes (T2D), dyslipidemia, and cardiovascular disease. It is associated with increased menstrual ir...
Lu C et al., 2022
Open Access
Clinical and Translational Medicine
Premature ovarian insufficiency (POI) is a disorder of ovarian function, which occurs in approximately 3.7% of women younger than 40 years of age.1 The aetiologies of most cases were unknown and usual...